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1. Introduction 
1.1 Overview of HIV-1/AIDS therapies 
In 1983, when researchers first isolated HIV-1 from an AIDS patient, few imagined that it 
foretold a worldwide pandemic (Broder & Gallo, 1984, Barre-Sinoussi et al., 1983). More 
than 25 years later, 65 million people have been infected with HIV-1; nearly half of these 
people have died of AIDS, and despite many scientific advances we are still without an 
efficacious vaccine (Merson, 2006). The majority of HIV-1 infections and deaths have 
occurred in developing countries, with sub-Saharan Africa accounting for over 38 million 
HIV-1 infections alone. Sadly, the number of new infections currently exceeds our ability to 
treat everyone infected with the virus, and in the hardest-hit countries the social and 
economic backlash has been profound.  
After HIV-1 was isolated, a blood test to screen patients and the blood supply quickly 
followed, as did research on its structure and pathogenesis. Many assumed that a vaccine 
would be available in a few years, and excitement increased further with the licensing of the 
first effective drug against HIV-1, zidovudine (AZT) (Fischl et al., 1987). However, 
researchers soon discovered that the virus was highly resilient, and HIV-1 quickly 
developed resistance to AZT (Poli et al., 1989, Richman et al., 1994). Over the next few years, 
a number of new antiretroviral drugs were developed that attacked the virus in different 
ways, and it was at this time that a new approach to therapy ensued. Highly active 
antiretroviral therapy (HAART) combined three or more different drugs to reduce HIV-1 
replication, and significantly improved the prognosis of HIV-1-infected individuals 
(Richman et al., 2009). However, HAART was not a cure, and many patients were resistant 
to at least one of the antiretroviral drugs. In addition, the drugs were highly toxic, making 
adherence to treatment difficult.  
During this time, the vaccine field was also hard at work, trying to develop a safe and 
effective HIV-1 vaccine. Most initial vaccine approaches focused on the HIV-1 envelope 
protein (gp120), and aimed to induce an antibody response to gp120. AIDSVAX was the first 
vaccine candidate of this type, and was developed by a U.S. pharmaceutical company called 
VaxGen (Flynn et al., 2005, Pitisuttithum et al., 2006). An alternative approach, developed by 
Merck, aimed to induce a T-cell response to HIV-1 using a recombinant adenovirus vector 
expressing HIV-1 Gag, Pol and Nef proteins (Shiver et al., 2002). Unfortunately, results from 
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both of these trials were disappointing, and neither approach provided protection from 
HIV-1 infection (Buchbinder et al., 2008, McElrath et al., 2008). Moreover, the Merck vaccine 
actually seemed to suppress the immune response, due to pre-existing immunity to the 
adenovirus vector (Priddy et al., 2008, Roberts et al., 2006).  
The third and largest trial was recently performed in Thailand, and aimed to induce both a 
T-cell and antibody response to HIV-1. In the study, 16,000 Thai men and women received 
either placebo or vaccine injections, and were subsequently monitored for HIV-1 infection 
over a 3 year period (Rerks-Ngarm et al., 2009). The vaccine group received injections of a 
recombinant canarypox vector vaccine ALVAC-HIV (Sanofi Pasteur), plus booster injections 
of a recombinant gp120 subunit vaccine AIDSVAX B/E (Global Solutions for Infectious 
Diseases). Results from this trial showed a modest benefit among vaccine recipients, with a 
vaccine efficacy of 26-30%. However, vaccination did not affect the levels of viremia or 
CD4+ T cell counts of infected individuals, and many were disappointed with the results 
(Rerks-Ngarm et al., 2009).  
Over the last decade, several host proteins have been identified that are capable of inhibiting 
HIV-1 replication (Figure 1). These so-called ‘cellular-restriction factors’ are a new arm of 
the innate immune system, and inhibit stages of the HIV-1 lifecycle that are not targeted by 
current AIDS therapies. Our understanding of how cellular restriction factors target HIV-1 
replication is far from compete, but research in this area may provide a new avenue for 
future AIDS therapies (Barr, 2010).  
 
 
Fig. 1. HIV-1/AIDS timeline. Timeline documenting major events in the HIV-1/AIDS 
pandemic, as well as the identification of several key HIV-1 cellular restriction factors.  
1.2 Cellular restriction factors 
Cellular restriction factors are host proteins that can inhibit specific steps in the lifecycle of a 
virus. The concept of cellular restriction factors first emerged in the 1970’s, when researchers 
identified strains of inbred mice that were resistant to Friend murine leukemia virus (MLV)-
induced leukemia (Lilly, 1967, Pincus et al., 1971). Interestingly, these studies showed that 
mice with certain ‘Friend virus susceptibility’ (Fv) loci, could inhibit MLV replication in vitro 
and were subsequently resistant to leukemia. The Fv1 and Fv4 genes were particularly 
interesting, and were later shown to encode host proteins that resembled virus components. 
The Fv1 gene encoded a protein that was similar to an endogenous retroviral Gag protein, 
and was shown to inhibit a post-entry stage of MLV replication (Ikeda et al., 1985). In 
contrast, the Fv4 gene encoded a protein that resembled env (envelope) sequences in a 
specific strain of MLV, which obstructed binding of wild-type MLV to target cells (Pryciak 
& Varmus, 1992).   
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Since these discoveries, several new cellular restriction factors have been identified, 
including a number of factors that restrict HIV-1 replication (Chakrabarti & Simon, 2010). 
Many of these restriction factors are up-regulated in response to type I interferons (IFNs), 
which are typically activated in the presence of viruses by pattern recognition receptors 
(PRRs), such as Toll-like receptors or retinoic acid induced gene (RIG)-like receptors 
(Kumagai et al., 2008). Following secretion, type I IFNs bind to the interferon ǂ/ǃ receptor 
(IFNAR) on the cell surface and induce signalling through the Janus Kinases/Signal 
Transducers and Activators of Transcription (Jak/Stat) pathway. This leads to the activation 
of hundreds of IFN-responsive genes that restrict viral replication, including cellular 
restriction factors (Baum & Garcia-Sastre, 2010) (Figure 2).  
Type I IFNs potently inhibit early and late stages of the HIV-1 lifecycle, and systemic 
administration of IFNǂ reduces HIV-1 plasma viremia in vivo (Meylan et al., 1993, Tavel et 
al., 2010). During viral infection, plasmacytoid dendritic cells (pDCs) are the main producers 
of IFNǂ, however the capacity of pDCs to produce IFNǂ is impaired during acute HIV-1 
infection, and this DC subtype appears to be depleted in chronic HIV-1 infection (Borrow & 
Bhardwaj, 2008, Soumelis et al., 2001). In addition, the HIV-1 accessory proteins Vpr and Vif 
can degrade interferon regulatory factor 3 (IRF-3), which plays a critical role in type I IFN 
induction (Okumura et al., 2008). Since cellular restriction factors are the ‘effector’ proteins 
of the IFN response, differences in the ability of pDCs to produce IFNǂ may contribute to 
differences in HIV-1 replication and disease progression among patients. Understanding the 
molecular mechanisms behind these HIV-1 restriction factors, may lead to the development 
of drugs that mimic or promote their activities. 
 
 
Fig. 2. The interferon response. Interferon (IFN) binds to the interferon receptor at the 
plasma membrane, activating the Janus Kinases/Signal Transducers and Activators of 
Transcription (Jak/Stat) pathway. This results in the up-regulation of hundreds of IFN-
responsive genes, including cellular restriction factors that prevent HIV-1 replication.  
1.3 The HIV-1 lifecycle 
The HIV-1 lifecycle offers a multitude of steps that can be targeted by cellular HIV-1 
restriction factors (Figure 3). The lifecycle begins when the HIV-1 envelope protein (gp120) 
binds to the host cell via its CD4 receptor, and following a conformational change, it binds 
to either the CXCR4 or CCR5 chemokine co-receptor (Deng et al., 1996). This interaction 
facilitates viral and cell membrane fusion, which is followed by the release of the viral core 
into the cell cytoplasm. In the cytoplasm, the HIV-1 capsid protein is lost in a process called 
uncoating, and the single-stranded RNA genome is reverse-transcribed into double-
stranded cDNA. Reverse transcription is carried out by the virion-associated reverse 
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transcriptase enzyme, and precedes the formation of the multimeric pre-integration 
complex. This complex, which consists of both host and viral proteins, is transported along 
microtubules to the nucleus, where the HIV-1 integrase enzyme facilitates integration of the 
viral cDNA into the host genome. Following integration, HIV-1 transcription occurs from 
the 5’ long terminal repeat (LTR) promoter, and leads to the synthesis of spliced HIV-1 RNA 
and unspliced HIV-1 genomic RNA. The RNA is exported into the cytoplasm where the 
main structural protein of HIV-1, the Gag polyprotein, is translated along with other viral 
proteins. The Gag protein oligomerizes and traffics to the cell membrane, where it forms 
higher-order structures and assembles into virions with other viral proteins. Cellular 
proteins are also involved in assembly, particularly Tsg101 and AIP1/ALIX, which 
participate in the budding and release of immature, non-infectious virions from the cell 
membrane (Garrus et al., 2001, Strack et al., 2003). As budding occurs, the Gag protein is 
cleaved into its four structural domains (matrix, capsid, nucleocapsid and p6) by the viral 
protease, generating mature infectious viral particles that are released from the cell 
membrane (Ganser-Pornillos et al., 2008, Ono, 2009). The following sections review the main 
HIV-1 cellular restriction factors in the order of their point of attack in the lifecycle, 
beginning with capsid uncoating and ending with viral release. 
2. Lifecycle target: HIV-1 capsid uncoating 
2.1 TRIM5α 
2.1.1 TRIM5α: History and background 
For years, researchers have been aware of a barrier to HIV-1 infection in Old world monkey 
(OWM) cells, however they have only recently begun to understand the nature of it. Early in 
the AIDS epidemic, the discovery that the host-range of HIV-1 was limited to humans and 
apes suggested that other primates may have an internal mechanism to combat HIV-1 
infection (Alter et al., 1984, Gajdusek et al., 1985, Lusso et al., 1988). A large number of 
mammalian cell lines were tested for susceptibility to HIV-1 infection, including cells 
derived from humans, OWMs (monkeys of African and Asian origin) and New world 
monkeys (NWM) (monkeys of Central and South American origin) (Hofmann et al., 1999). 
Interestingly, HIV-1 replication was blocked in most OWM-derived cell lines and one 
species of NWM, the Owl monkey. Because of its initial definition as a genetic barrier to 
lentiviral infection, the restriction factor was originally named lentivirus susceptibility 
factor-1 (Lv-1) (Cowan et al., 2002).   
TRIM5ǂ was not identified as the protein responsible for the OWM block until it was 
isolated during a cDNA screen of HIV-1 resistant rhesus macaque cells. In the study, a 
cDNA library was created from HIV-1 resistant rhesus macaque cells and the cDNA clones 
from this library were transduced into an HIV-1 sensitive human cell line (HeLa) (Stremlau 
et al., 2004). The human cells were then challenged with HIV-1 and screened for resistant 
clones, which identified the rhesus orthologue of TRIM5ǂ (rhTRIM5ǂ). Excitingly, around 
the same time, TRIM5ǂ was also linked to the HIV-1 block in Owl monkey cells; however, 
the Owl monkey version of TRIM5α encoded a TRIM5ǂ-cyclophilin A fusion protein (Sayah 
et al., 2004). Cyclophilin A (CypA) was previously shown to bind to the HIV-1 capsid 
protein and promote HIV-1 replication in human cells; however, in Owl monkey cells CypA 
seemed to restrict HIV-1 (Luban, 2007, Sokolskaja & Luban, 2006). The discovery of a 
TRIM5ǂ-CypA fusion protein explained these results and indicated that CypA may target 
TRIM5ǂ-CypA to incoming HIV-1 capsid proteins.   
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Fig. 3. The HIV-1 lifecycle. The HIV-1 envelope protein (Env) binds to the CD4+ receptor 
and CXCR4/CCR5 co-receptor on the host cell. The viral core is released into the 
cytoplasm, where the RNA genome is reverse-transcribed into double-stranded cDNA. 
The cDNA is imported into the nucleus, where it integrates into the host genome. The 
viral genes are transcribed and the RNA is exported to the cytoplasm, where it is 
translated into protein. The viral proteins traffic to the membrane where they assemble 
and bud out of the host cell.  
2.1.2 TRIM5α: Structure and function 
TRIM5ǂ belongs to the tripartite motif-containing (TRIM) family of proteins, of which there 
are currently 77 identified members (Nisole et al., 2005). Although the TRIM5 gene gives rise 
to several isoforms through differential splicing, TRIM5ǂ is the only isoform with potent 
anti-HIV-1 activity. All TRIM proteins have a conserved RBCC motif, which consists of a 
RING domain, one or two B-box domains and a predicted coiled-coil region. The majority of 
TRIM proteins, including TRIM5ǂ, have a C-terminal B30.2 domain. The Really Interesting 
New Gene (RING) domain has intrinsic E3 ligase activity, and together with an E1 
activating enzyme and an E2 conjugating enzyme it can transfer ubiquitin or ubiquitin-like 
molecules to target proteins (Ozato et al., 2008). This modification can alter a protein’s half-
life, subcellular localization or interaction with other proteins. Importantly, two RING 
domain cysteine residues (C15 and C18) are essential for the E3 ligase activity of the RING 
domain (C15 and C18). These two residues are also required by rhTRIM5ǂ for restricting 
HIV-1 replication (Diaz-Griffero et al., 2006).  
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The function of the B-box domain remains largely uncharacterized; however, it is an 
interesting domain because it is unique to TRIM proteins. Deletion of the B-box domain of 
TRIM5ǂ eliminates the ability of TRIM5ǂ to restrict HIV-1, suggesting that this domain is 
critical for TRIM5ǂ-mediated restriction (Stremlau et al., 2004, Javanbakht et al., 2005, Li & 
Sodroski, 2008, Perez-Caballero et al., 2005). In addition, it was recently shown that the B-
box domain promotes HIV-1 capsid binding by mediating higher-order self-association (Li 
& Sodroski, 2008). The coiled-coil region is involved in protein-protein interactions and 
more specifically, it is thought to mediate TRIM5ǂ oligomer formation. It has been proposed 
that oligomer formation is important for positioning the B30.2 domain of TRIM5ǂ for 
optimal HIV-1 capsid binding and accordingly, TRIM5ǂ coiled-coil mutants fail to restrict 
HIV-1 (Perez-Caballero et al., 2005, Javanbakht et al., 2006). Finally, the specificity and 
interspecies variability of TRIM5ǂ is found in the B30.2 domain. Sequence analysis has 
shown a significant amount of interspecies variability within the B30.2 domain of both 
NWM and OWM, especially on several variable loops that are thought to form the binding 
surface for HIV-1 capsid recognition (Ohkura et al., 2006, Woo et al., 2006, Yao et al., 2006).   
2.1.3 TRIM5α-mediated HIV-1 restriction 
To date, rhTRIM5ǂ is the earliest-acting HIV-1 restriction factor and targets virus replication 
immediately after HIV-1 entry into target cells. Several studies have shown that rhTRIM5ǂ 
blocks reverse transcription and nuclear import of viral cDNA. The mechanisms underlying this 
restriction are thought to include: sequestration of the virus core in the cytoplasm, modification 
of the virus core leading to degradation, or interference in the trafficking of the preintegration 
complex (Bieniasz, 2004, Chatterji et al., 2006, Stremlau et al., 2006). The most favoured 
mechanism involves rhTRIM5ǂ binding to the viral core and disrupting the normal uncoating 
process of the core (Figure 4). This binding involves the recognition of specific sequences 
 
 
Fig. 4. TRIM5ǂ-mediated HIV-1 restriction. RhTRIM5ǂ binds to incoming HIV-1 capsid 
proteins via its B30.2 domain, causing them to rapidly dissociate and prematurely 
disassemble. This leads to a block in HIV-1 reverse transcription and inhibits nuclear import 
of viral cDNA, restricting further propagation of the virus.  
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on the HIV-1 capsid by the B30.2 domain of rhTRIM5ǂ and subsequent block at the level of 
reverse transcription. Interestingly, human TRIM5ǂ (huTRIM5ǂ) only modestly inhibits HIV-1 
replication and substitution of a single amino acid (R332) in its B30.2 domain enables it to 
restrict HIV-1 as potently as rhTRIM5ǂ (Yap et al., 2005).  
3. Lifecycle target: HIV-1 reverse transcription 
3.1 APOBEC3 
3.1.1 APOBEC3: Structure and function 
The human apolipoprotein B mRNA-editing catalytic polypeptide-like 3 (APOBEC3) family 
is part of a larger family of APOBEC cytidine deaminases, capable of converting cytosine to 
uracil in RNA or DNA. The APOBEC3 family is found on chromosome 22 and contains 
seven members (A-H), which are believed to be the result of multiple duplication events 
(Conticello et al., 2005). Interestingly, APOBEC3 proteins appear to be under positive 
selective pressure, possibly as a defence against endogenous retroelements, and have been 
shown to have antiviral activity against a variety of viruses, including murine leukemia 
virus, human T-lymphotropic virus, simian immunodeficiency virus and the recently 
discovered Xenotropic Murine leukemia virus-Related Virus (XMRV) (Sawyer et al., 2004, 
Sawyer et al., 2004, Groom et al., 2010, Groom et al., 2010, Aguiar & Peterlin, 2008, 
Niewiadomska & Yu, 2009). In addition, all seven members have been implicated in HIV-1 
restriction, however APOBEC3F/G are the best studied and appear to be the most potent 
restrictors (Hultquist & Harris, 2009).   
Before APOBEC3 proteins were specifically identified, it was discovered that HIV-1 clones 
with the accessory protein Vif deleted were capable of replicating in certain cell lines. These 
cells were termed “permissive cells”, and included HeLa, HEK 293T, SupT1 and CEM-SS 
lines. In other cells, such as primary human T-lymphocytes or macrophages, or the H9 and 
CEM T cell lines, virions produced from Vif-deficient strains were up to 1,000 times less 
infectious compared to virions from wild-type strains (Gabuzda et al., 1992). Cell fusion 
experiments revealed that this “non-permissive” phenotype was dominant, and comparison 
of the related CEM T and CEM-SS cell lines revealed a 1.5 kb cDNA segment expressed in 
CEM T cells that was not produced in CEM-SS cells (Madani & Kabat, 1998, Sheehy et al., 
2002, Simon et al., 1998). This protein, termed CEM15 and later renamed APOBEC3G (A3G), 
was shown to be suppressed by Vif, thus resulting in productive infection of non-permissive 
cells with wild-type HIV-1 (Sheehy et al., 2002). 
3.1.2 APOBEC3-mediated HIV-1 restriction 
In the absence of Vif, A3G is packaged into newly formed virions and blocks HIV-1 
replication after infection of a new cell. Two mechanisms of HIV-1 inhibition have been 
reported for A3G: 1) the production of hyper-mutated viral DNA and 2) decreased 
accumulation of viral DNA (Figure 5) (Anderson & Hope, 2008, Bishop et al., 2008, Lecossier 
et al., 2003, Mangeat et al., 2003, Simon & Malim, 1996). During reverse transcription, A3G 
induces cytidine deamination (CU mutations) in the negative strand of newly synthesized 
viral cDNA. The latter results in GA hyper-mutated viral DNA and increases the 
probability of producing premature stop codons or mutated, non-functional viral proteins. 
Interestingly, cytidine deamination also recruits cellular uracil-DNA glycosylases that cleave 
off the uracil side chain as part of the base-excision repair pathway. The resulting abasic site 
may then prevent plus-strand DNA synthesis or lead to degradation of viral DNA by 
endonucleases (Klarmann et al., 2003, Yang et al., 2007). However, there is some controversy 
over the degree to which APOBEC3-mediated cytidine deamination contributes to reduced 
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accumulation of HIV-1 DNA, and it has been reported that the HIV-1 accessory protein Vpu 
induces the degradation of certain cellular uracil-DNA glycosylases (Schrofelbauer et al., 
2005). Furthermore, loss of certain uracil-DNA glycosylases does not appear to affect 
APOBEC3 restriction of HIV-1, and similar results have been obtained for A3G restriction of 
other viruses (Kaiser & Emerman, 2006, Nguyen et al., 2007). Nevertheless, this does not 
rule out the possible involvement of other glycosylases, and additional studies will be 
required to fully elucidate the effects of APOBEC3 cytidine deaminase activity on HIV-1 
replication. 
Cytidine deaminase mutants of both A3F and A3G still retain a degree of anti-HIV-1 
activity, and both proteins have been shown to affect the initiation of reverse transcription 
by interfering with tRNA3Lys binding to viral RNA. In addition, A3G has been shown to 
inhibit both plus and minus strand transfer RNA integration and DNA elongation during 
reverse transcription (Hultquist & Harris, 2009). Interestingly, endogenous A3G in resting 
naive and memory CD4+ T cells may inhibit newly infecting virus, contributing to the 
known resistance of quiescent T cells to HIV-1 infection (Chiu et al., 2005, Muckenfuss et al., 
2006). In this model, A3G can exist in two forms: an inactive high molecular mass complex 
(HMM) in activated T cells or an enzymatically active low molecular mass form (LMM) in 
resting T cells. Since A3G can interfere with multiple steps of reverse transcription, this 
hypothesis is consistent with infection of resting T cells, in which cDNA synthesis is 
initiated, but the viral genome is not completely reverse transcribed.  
 
 
Fig. 5. APOBEC3G-mediated restriction of Vif-deficient HIV-1. APOBEC3G (A3G) is 
packaged into newly formed virions and interferes with viral replication upon infection of 
new cells. A3G directly interferes with reverse transcription, resulting in decreased amounts 
of viral cDNA. In addition, A3G acts as a cytidine deaminase, inducing CU mutations in 
minus-strand viral cDNA. This leads to base excision by cellular uracil-DNA glycosylases or 
uracil bases are replaced with thymine, resulting in extensiveGA hypermutations in the 
viral genome.  
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In recent years, the resting T cell theory has received criticism, mainly because several 
results in the original work were not repeatable. However, it should be noted that many 
results were still repeatable including the presence of LMM/HMM in resting/activated T 
cells and the enzymatically active nature of LMM forms (Chiu et al., 2005). Furthermore, it 
was observed that factors such as IL-2 and IL-15 both increase susceptibility of resting T 
cells to HIV-1 infection and induce a shift of A3G organization from LMM to HMM forms, 
suggesting that these results may warrant further investigation. In addition, several 
APOBEC3 proteins appear to have cytidine deaminase-independent antiviral activity 
against Hepatitis B virus, Adeno-associated virus, and a number of retroelements, further 
supporting the existence of a cytidine deaminase-independent antiviral mechanism (Bogerd 
et al., 2006, Chen et al., 2006, Stenglein & Harris, 2006, Turelli et al., 2004). As such, the 
extent to which cytidine deaminase-dependent or –independent functions contribute to the 
antiviral activity of APOBEC3 proteins against HIV-1 requires further elucidation. 
3.1.3 Countermeasures to APOBEC3-mediated HIV-1 restriction 
Vif restores HIV-1 infectivity by inducing the degradation of APOBEC3 proteins (Conticello et 
al., 2003, Marin et al., 2003, Sheehy et al., 2003). Vif and APOBEC3 proteins physically interact 
with each other, and these interactions are specific, however they differ depending on the 
APOBEC3 member being targeted (Niewiadomska & Yu, 2009). Vif also contains several 
conserved elements that allow it to form a complex with certain cellular proteins. Specifically, 
the SLQxLA motif in Vif interacts with ElonginC, allowing the recruitment of ElonginB and 
Cul5, which bind Vif through another conserved motif. Rbc1 is also recruited to the complex, 
creating an E3 ligase capable of polyubiquitinating APOBEC3 proteins and targeting them for 
26S proteasomal degradation (Figure 6) (Kobayashi et al., 2005, Mehle et al., 2004,  
 
 
Fig. 6. Vif-mediated degradation of APOBEC3. Vif interacts with cellular factors to create 
a Skp1-cullin-F-box (SCF)-like complex that polyubiquitinates and degrades APOBEC3 
molecules. Vif binds Cullin5 (Cul5) through two conserved motifs and other cellular factors, 
forming a scaffold for other E3 ligase components.  
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Yu et al., 2003). Interestingly, one report suggests that Vif instead of A3G is actually 
polyubiquitinated, possibly to serve as a way to transport A3G to the 26S proteasome for 
degradation (Dang et al., 2008). However, mutated and modified forms of Vif that are still 
capable of degrading A3G are unable to restore viral infectivity (Mehle et al., 2004, Kao et al., 
2007). Thus, Vif may also inhibit A3G through degradation-independent mechanisms. Possible 
theories include a competitive inhibition model, where Vif binds to a common target, 
preventing A3G packaging, or that Vif inactivates A3G by inducing the formation of high 
molecular mass complexes (Goila-Gaur & Strebel, 2008, Goila-Gaur et al., 2008). 
3.1.4 APOBEC3: Effects on HIV-1 replication in vivo  
The extent to which APOBEC3 proteins are functional during HIV-1 infection in vivo is a 
highly contested topic. One report has observed the presence of extensive GA 
hypermutation in virus samples collected from one HIV-1 long-term non-progressor (Wang 
et al., 2003)(Kao et al., 2007)(Kao et al., 2007)(Kao et al., 2007)(Kao et al., 2007)(Kao et al., 
2007)(Kao et al., 2007)(Kao et al., 2007). Although this may suggest a role for APOBEC3 in 
controlling infection, it appears to be the only reported case, and thus the effects of 
APOBEC3 may have been secondary to some other mechanism of control. Still, it is possible 
that APOBEC3 proteins are more functional in certain patients/infections than in others. 
There are reports of both significant correlations and lack of correlation, between 
hypermutation and reduced viral load/higher CD4+ cell counts (Land et al., 2008, 
Piantadosi et al., 2009, Ulenga et al., 2008). Though hypermutation-independent 
mechanisms may exist, other groups have shown a negative correlation between A3G 
mRNA expression levels and HIV-1 viremia, and a positive correlation between A3G mRNA 
levels and CD4+ cell counts (Ulenga et al., 2008, Vazquez-Perez et al., 2009). Furthermore, it 
was shown that A3F/G mRNA levels post-infection are higher in patients with low viral set 
points than in patients with high viral set points, and higher in seronegative patients 
compared to healthy controls. Nevertheless, another group observed no correlation between 
A3F/G mRNA levels and viremia or CD4+ cell counts (Cho et al., 2006). Although 
conflicting reports exist, these may, in part, be explained by varying levels of APOBEC3 
mRNA between donors (Koning et al., 2009). More detailed studies into both APOBEC3 
expression and activity at the host level, in addition to correlation with disease progression, 
will be required to further elucidate its relationship to HIV-1 infection. 
4. Lifecycle target: HIV-1 RNA  
4.1 PKR 
4.1.1 PKR: Structure and function 
Protein kinase R (PKR) is constitutively expressed in human cells as an inactive monomer. 
In the presence of double-stranded RNA (dsRNA), which forms the genetic material of some 
viruses, PKR forms a dimer and phosphorylates itself to become active (Dey et al., 2005, 
Garcia et al., 2007). Activation of PKR is also possible through type I IFN signalling, and 
PKR is upregulated in the presence of IFNs. PKR contains a N-terminal dsRNA binding 
domain (dsRBD), which is made up of two dsRBD motifs and can bind to dsRNA as short as 
30bp (Figure 1) (Lemaire et al., 2008). Dimerization relies strongly on the dsRBD, and studies 
deleting this domain show impaired dimerization as well as lack of PKR activation 
(Cosentino et al., 1995). In addition to its dsRBD, PKR contains a C-terminal kinase domain 
that has intrinsic phosphotransferase activity. This function hinges on a key lysine residue at 
position 296, without which the kinase domain is inactive (Sadler et al., 2009).   
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4.1.2 PKR-mediated inhibition of HIV-1 transcription 
Upon activation, PKR inhibits HIV-1 replication through a number of different mechanisms.  
One mechanism involves phosphorylation of the enzyme RNA Helicase A (RHA), which 
has been shown to enhance HIV-1 transcriptional activity and binds to the HIV-1 trans-
activation response (TAR) element (Fujii et al., 2001, Jeang & Yedavalli, 2006). The HIV-1 
TAR element is required for trans-activation of the viral promoter and binds to the viral 
trans-activator of transcription (Tat) protein. This interaction greatly increases transcription 
of viral genes from the HIV-1 promoter, and results in the production of many full-length 
HIV-1 transcripts. The TAR element is an unusual stem-loop RNA structure that is located 
at the 5’ end of all HIV-1 mRNAs (Adelson et al., 1999, Nagai et al., 1997). PKR recognizes 
TAR RNA as dsRNA, and it binds to the upper bulge of the lower stem-loop structure using 
both of its dsRNA binding motifs (Carpick et al., 1997, Kim et al., 2006). 
Like PKR, RHA contains a dsRBD with two dsRNA binding motifs, which are required for 
TAR recognition and binding (Fujii et al., 2001). A lysine residue at position 236 of RHA is 
essential for TAR binding (Fujii et al., 2001, Jeang & Yedavalli, 2006). Recently, PKR has been 
shown to phosphorylate the dsRBD of RHA; a modification that depends on lysine 296 of 
the PKR protein (Sadler et al., 2009).  Phosphorylation of RHA by PKR seems to inhibit 
RHA-TAR binding, which in turn decreases the levels of HIV-1 mRNA transcripts (Sadler et 
al., 2009).   
4.1.3 PKR-mediated inhibition of HIV-1 translation 
Upon activation, PKR inhibits HIV-1 replication through a number of different mechanisms.  
The most widely researched pathway occurs through PKR-mediated phosphorylation of the 
alpha subunit of the eukaryotic initiation factor 2 (eIF2ǂ), a key regulator of protein 
synthesis (Figure 7) (Dey et al., 2005, Rojas et al., 2010). In eukaryotic cells, eIF2ǂ bound to 
GTP mediates the formation of a trimeric complex with methionine transfer RNA (met-
tRNA).  This complex leads to met-tRNA binding to the 40S ribosomal subunit, and allows 
for the initiation of translation (Rojas et al., 2010, Nallagatla et al., 2011). However, 
phosphorylation of eIF2ǂ by PKR prevents the eIF2ǂ-GTP interaction and eliminates the 
formation of the trimeric complex, thus inhibiting translation of all mRNA, including viral 
mRNA (Nallagatla et al., 2011).   
The HIV-1 trans-activation response (TAR) element is required for trans-activation of the 
viral promoter and binds to the viral trans-activator of transcription (Tat) protein. This 
interaction greatly increases viral gene expression from the HIV-1 promoter by inducing 
chromatin remodelling and by recruiting elongation-competent transcriptional complexes 
onto the viral LTR. The TAR element is an unusual stem-loop RNA structure that is located 
at the 5’ end of all HIV-1 mRNAs (Adelson et al., 1999, Nagai et al., 1997). PKR recognizes 
TAR RNA as dsRNA, and it binds to the upper bulge of the lower stem-loop structure using 
both of its dsRNA binding motifs (Carpick et al., 1997, Kim et al., 2006). This leads to 
activation of PKR and phosphorylation of eIF2ǂ, which subsequently inhibits protein 
translation (Nallagatla et al., 2011, Roy et al., 1991) 
4.1.4 Countermeasures to PKR-mediated HIV-1 restriction 
Although in vitro studies have shown that PKR can inhibit HIV-1 replication, in vivo models 
of infection fail to exhibit viral restriction. Interestingly, low levels of dsRNA have been 
shown to have beneficial effects on PKR activation; however, higher levels of dsRNA 
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(greater than a 1:1 ratio of dsRNA:PKR) may actually inhibit PKR activity (Chu et al., 1998, 
Hunter et al., 1975). During the initial stages of HIV-1 infection, low levels of TAR RNA 
(dsRNA) are produced and this leads to PKR activation (Lemaire et al., 2008). Conversely, in 
later stages of viral replication (when Tat-TAR binding enhances transcription), much more 
TAR RNA (dsRNA) is generated, which seems to inhibit PKR activity (Lemaire et al., 2008, 
Hunter et al., 1975, Clerzius et al., 2011, Manche et al., 1992). It has been proposed that high 
concentrations of dsRNA cause PKR to bind dsRNA as a monomer, which inhibits PKR 
dimerization and subsequent activation (Manche et al., 1992, Cole, 2007).  
PKR activation is also interrupted by the HIV-1 Tat protein. Tat binds to the HIV-1 TAR 
element and in doing so, masks TAR recognition by PKR and inhibits PKR activation (Cai et 
al., 2000). Furthermore, Tat binds to PKR directly and therefore competes for PKR binding 
with eIF2ǂ (Brand et al., 1997). There is a high degree of sequence homology between the 
Tat and eIF2ǂ binding sites in PKR, which leads to a decrease in eIF2ǂ phosphorylation (Cai 
et al., 2000, Brand et al., 1997). In addition, Tat binding to PKR inhibits autophosphorylation, 
possibly by inhibiting PKR dimerization, which is necessary for its antiviral activity (Cai et 
al., 2000, Brand et al., 1997). There is also evidence that phosphorylation of Tat by PKR at 
several key amino acids (S62, T64, S68) actually enhances Tat’s ability to initiate 
transcription; however, the precise mechanism of transcriptional enhancement is not yet 
clear (Endo-Munoz et al., 2005).  
 
 
Fig. 7. PKR-mediated inhibition of HIV-1 protein translation. PKR recognizes the HIV-1 TAR 
element (dsRNA) and dimerizes and phosphorylates itself to become active. Active PKR 
phosphorylates eIF2ǂ, preventing guanine nucleotide exchange and eIF2ǂ activation. 
Inactive eIF2ǂ is unable to transfer methionine-tRNA to the 40S ribosome for mRNA 
translation, and protein translation is inhibited.   
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4.2.1 TRIM22: Structure and function 
Tripartite motif-containing protein 22 (TRIM22) was originally isolated during a search for 
IFN-induced genes in Daudi cells, and is located at chromosomal position 11p15, 
immediately adjacent to the TRIM5ǂ gene (Tissot & Mechti, 1995). Similar to TRIM5ǂ, 
TRIM22 belongs to the TRIM family of proteins and is upregulated in response to Type I 
and Type II IFNs (Bouazzaoui et al., 2006). TRIM22 expression is altered by multiple 
cytokines and viral antigens/infections, including Hepatitis B virus, encephalomyocarditis 
virus, and HIV-1 (Gao et al., 2009, Gao et al., 2009, Eldin et al., 2009). TRIM22 may also play 
a role in cellular processes such as cell differentiation/proliferation, as it is a known p53 
target gene and has been suggested to have potential anti-proliferative functions (Obad et 
al., 2004, Obad et al., 2007). 
To date, several studies have addressed the effect of TRIM22 on HIV-1 replication. 
TRIM22 expression was first shown to reduce HIV-1 transcription from a luciferase 
reporter construct under control of the HIV-1 long terminal repeat promoter (LTR) (Tissot 
& Mechti, 1995). Although this report did not follow up these observations in the context 
of full-length, replication competent HIV-1, it was fundamental in identifying TRIM22 as 
a potential HIV-1 restriction factor. Eleven years later, TRIM22 expression was shown to 
be increased in response to ex vivo HIV-1 infection of primary monocyte-derived 
macrophages, a biological target of HIV-1 (Bouazzaoui et al., 2006). In addition, 
overexpression of TRIM22 restricted HIV-1 infection by 70-90% and prevented the 
formation of syncytia. In 2008, TRIM22 was confirmed to be a potent effector of the IFN 
response against HIV-1 infection, and two different methods of TRIM22-mediated late-
stage HIV-1 restriction were observed: one dependent on, and a second independent of, 
the HIV-1 Gag polyprotein (Barr et al., 2008).  
4.2.2 TRIM22-mediated inhibition of HIV-1 transcription 
It has since been confirmed that TRIM22 is capable of restricting HIV-1 mediated 
transcription (Kajaste-Rudnitski et al., 2011). Different clones of the U937 promonocytic cell 
line have previously been identified to be either permissive or nonpermissive to HIV-1 
replication (Franzoso et al., 1994). Examination of multiple IFN-induced restriction factors 
revealed that only TRIM22 was present in nonpermissive clones and absent in permissive 
clones. LTR-driven transcription between permissive and nonpermissive clones was 
examined using a reporter construct expressing luciferase under control of the HIV-1 LTR. 
Basal transcription levels were decreased 7-10 fold in nonpermissive clones, but recovered 
to levels observed in permissive cells when shRNA was used to knockdown TRIM22 
expression. Furthermore, LTR-driven transcription was decreased in permissive cells 
transduced with TRIM22, suggesting that the constitutive expression of TRIM22 is 
responsible for the restrictive phenotype observed in nonpermissive clones (Kajaste-
Rudnitski et al., 2011). Reduced LTR-driven luciferase expression and HIV-1 replication 
were also observed in A3.01 cells (T cell line) expressing TRIM22, further supporting the 
effects of TRIM22 on HIV-1 infection in critical cell targets (Kajaste-Rudnitski et al., 2011). 
TRIM22 appears to strongly target basal transcription from the HIV-1 LTR. In further 
experiments using LTR-driven luciferase constructs, TRIM22 had no effect on transcription 
when cells were transfected with a plasmid encoding the HIV-1 Tat protein (Kajaste-
Rudnitski et al., 2011). Although statistical significance was not reached, this may be due to 
the effects of exogenously provided Tat masking the efficacy of TRIM22. It should also be 
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noted that all direct evidence to date of TRIM22 inhibiting HIV-1 transcription has been 
through the use of LTR-driven reporter constructs. It will be important to test the effects of 
TRIM22 on replication-competent HIV-1, which will provide a more natural scenario of 
virus transcription, Tat-induction, and possible effects of other HIV-1 accessory proteins. 
4.2.3 TRIM22-mediated effects on HIV-1 replication in vivo 
Interestingly, there is evidence to support a role for TRIM22 as an anti-HIV effector in vivo. 
A study monitoring gene expression in high-risk HIV-1 negative individuals detected a 
positive correlation between TRIM22 expression and increased control of HIV-1 infection 
(Singh et al., 2011). It was observed that IFNǃ and TRIM22 levels in peripheral blood 
mononuclear cells (PBMCs) were increased in patients after HIV-1 infection. In addition, 
infected patients expressing higher TRIM22 levels exhibited significantly lower viral loads 
and significantly higher CD4+ T cell counts, suggesting that TRIM22 may play a role in 
controlling HIV-1 infection. Surprisingly, a significant inverse correlation was observed 
between the closely related, IFN-inducible TRIM5ǂ protein and IFNǃ expression (Singh et 
al., 2011). TRIM22 and TRIM5ǂ have been under positive selection episodically for 
approximately 23 million years; however, these two genes have evolved in a mutually 
exclusive manner, with only one being selected for in a given primate lineage (Sawyer et al., 
2007). Since human TRIM5ǂ has little to no inhibitory effect on HIV-1 replication compared 
to the potent inhibitory effects of rhesus TRIM5ǂ, it is possible that human TRIM22 has 
evolved to compensate for the loss of antiretroviral activity of human TRIM5ǂ.  
5. Lifecycle target: HIV-1 protein  
5.1 OAS1/RNaseL 
5.1.1 OAS1/RNaseL-mediated inhibition of HIV-1 translation 
Similar to PKR, 2’5’ oligoadenylate synthetase 1 (OAS1) senses viral infection by recognizing 
dsRNA, and is constitutively expressed in an inactive monomeric form (Sadler et al., 2009). 
However, unlike PKR, OAS1 recognizes dsRNA in the absence of a dsRBD. Exactly how 
OAS1 recognizes dsRNA without this domain remains unclear (Kodym et al., 2009, Marie et 
al., 1990, Sadler & Williams, 2008). Once OAS1 is activated by dsRNA, it forms a tetramer, 
which converts ATP molecules into 2’5’ oligoadenylates (2-5A) (Marie et al., 1990, 
Hovanessian, 2007). These 2-5As are strong inducers of an enzyme called RNaseL. By 
binding to the N-terminus of RNaseL, 2-5As activate the ribonuclease activity of RNaseL, 
which then degrades single-stranded RNA (ssRNA) by cleaving the phosphodiester bonds 
of uracil rich sequences to produce products with 3’ monophosphate and 5’ hydroxyl 
termini (Chakrabarti et al., 2011, Malathi et al., 2007). This leads to a reduction in mRNA 
translation and induces the RIG-I and/or MDA5 pathways, which are positive regulators of 
interferon signalling and the antiviral response (Figure 8) (Malathi et al., 2007).  
The HIV-1 TAR element (dsRNA) is sufficient for OAS1 recognition and activation, and 
OAS1-TAR binding leads to 2-5A production, RNaseL recognition, cleavage of HIV-1 
transcripts and inhibition of protein translation (Maitra et al., 1994). Interestingly, Jurkat T 
cells that overexpress RNaseL show a substantial decrease in HIV-1 mRNA production, as 
well as a 1000-fold decrease in HIV-1 replication two weeks post-infection (Maitra & 
Silverman, 1998). In addition, overexpression of RNaseL leads to accelerated HIV-induced 
apoptotic cell death, possibly through Fas-Fas ligand-mediated signalling (Maitra & 
Silverman, 1998). In contrast, cells devoid of RNaseL are unable to restrict HIV-1 replication, 
highlighting the importance of this pathway in cellular restriction of virus replication.     
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5.1.2 Countermeasures to OAS1/RNaseL-mediated HIV-1 restriction 
Overexpression studies have shown that OAS1/RNaseL-mediated HIV-1 restriction is 
possible; however, when RNaseL is expressed at biologically relevant levels, HIV-1 can 
inhibit this pathway. The HIV-1 Tat protein sequesters the TAR element in vivo, thus 
preventing OAS1-TAR binding and RNaseL activation (Schroder et al., 1990b). It is possible 
that this pathway is responsible for the low levels of mRNA production during the initial 
stages of HIV-1 infection; however, as Tat expression increases, activation of the 
OAS1/RNaseL pathway decreases and the production of HIV-1 mRNA rises significantly. 
In addition, cells that contain latent virus may be kept under control by the OAS1/RNaseL 
pathway. Nevertheless, the ability of cells to endocytose Tat from other apoptotic cells may 
lead to trans-activation of the TAR element and HIV-1 mRNA production in these latently 
infected cells (Schroder et al., 1990b, Frankel & Pabo, 1988).   
Although PKR and OAS1/RNaseL are potent HIV-1 restriction factors in vitro, the HIV-1 Tat 
protein is an effective viral countermeasure in vivo. Research on these restriction factors 
however, does provide insight into future therapeutics that may target the HIV-1 Tat 
protein, or overpower Tat for TAR binding. In vitro studies have already shown that shRNA 
directed against Tat or a TAR RNA decoy can provide long-term inhibition of HIV-1 
replication; however, these studies must still be confirmed in vivo (Li et al., 2005).  
5.2 TRIM22 
5.2.1 TRIM22-mediated HIV-1 restriction 
Interestingly, TRIM22 appears to restrict HIV-1 replication by multiple mechanisms. 
TRIM22 has been shown to be an integral part of IFNǃ-mediated HIV-1 restriction, and its 
expression can restrict HIV-1 replication in several transformed cell lines. In cell lines such 
as human osteosarcoma (HOS) and HeLa, TRIM22 restricts the release of virus, but has little 
to no effect on intracellular levels of the HIV-1 structural protein Gag. Conversely, in the 
osteosarcoma cell lines U2OS and 143B, TRIM22 expression not only restricts the release of 
virus, but also prevents the intracellular accumulation of Gag protein (Barr et al., 2008). The 
presence of different mechanisms in different cell lines, and the fact that multiple 
localizations for TRIM22 have been observed, suggests that there are many complex details 
of TRIM22 function that remain to be discovered (Figure 9). 
Further investigation of the mechanism of TRIM22-induced restriction in HOS cells revealed 
that TRIM22 likely interferes with intracellular trafficking of the HIV-1 Gag protein (Barr et 
al., 2008). Of note, Gag is both necessary and sufficient for budding and release of virus 
particles. This property allows Gag, in the absence of other viral proteins, to assemble and 
bud from the cell membrane, resulting in the production of non-infectious, virus-like 
particles (VLP). Importantly, TRIM22 expression was shown to inhibit the release of VLPs 
and prevent accumulation of Gag at the cell membrane, a step that is critical for virus 
assembly. These effects were dependent on the E3 ubiquitin ligase activity of TRIM22.  
5.3 TRIM5α 
5.3.1 TRIM5α-mediated HIV-1 restriction 
RhTRIM5ǂ was originally shown to target incoming HIV-1 capsid proteins, thus inhibiting 
early stages of HIV-1 replication (see Section 2.1). For this reason, it was initially assumed 
that rhTRIM5ǂ didn’t affect late stages of HIV-1 replication. However, subsequent research 
showed that it could also restrict HIV-1 through rapid degradation of the Gag polyprotein, 








Fig. 8. OAS1/RNaseL-mediated inhibition of HIV-1 protein translation. Following 
recognition of the HIV-1 TAR element (dsRNA), OAS1 forms a tetramer whose catalytic 
activity turns ATP molecules into 2'5'oligoadenylates (2-5As). The 2-5As activate the RNaseL 
enzyme, which leads to its dimerization and stimulates it to cleave ssRNA (such as mRNA). 
Cleavage of mRNA by RNaseL results in the inhibition of protein translation, including the 
translation of viral proteins. 
with the proteasome inhibitors MG132 and MG115 did not restore HIV-1 Gag protein 
stability, suggesting that late restriction by rhTRIM5ǂ occurs independently of the 
ubiquitin/proteasome system. Interestingly, similar to early-stage restriction, the human 
orthologue of rhTRIM5ǂ did not restrict late stages of HIV-1 replication (Sakuma et al., 2007, 
Sakuma et al., 2007, Sakuma et al., 2010). 
Unlike early-stage rhTRIM5ǂ-mediated restriction, the B30.2 domain was dispensable for 
Gag degradation. However, two amino acids in the coiled-coil domain (M133 and T146) and 
the E3 ligase activity of rhTRIM5ǂ were required for late-stage restriction (Sakuma et al., 
2010). It is possible that rhTRIM5ǂ acts synergistically with other TRIM proteins or cell 
proteases to degrade the Gag polyprotein. For example, TRIM22 has been shown to affect 
late stages of HIV-1 replication and thus may be involved in rhTRIM5ǂ-mediated restriction 
(Barr et al., 2008). Additional research will determine if other TRIM proteins are involved 
and help define the exact mechanism of late-stage rhTRIM5ǂ-mediated restriction.   
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Fig. 9. Possible mechanisms of TRIM22-mediated HIV-1 restriction. TRIM22 prevents 
accumulation of the Gag polyprotein at the plasma membrane, and as such may bind 
directly to Gag. Alternatively, TRIM22 may mono-ubiquitinate or polyubiquitinate Gag. 
Experiments using LTR-luciferase reporter constructs have also shown that TRIM22 restricts 
transcription from the 5’ HIV-1 LTR.  
6. Lifecycle target: HIV-1 budding 
6.1 ISG15 
Interferon-stimulated gene 15 (ISG15) is a ubiquitin-like protein (Ubl) that was first 
discovered in 1979, and is highly induced in the presence of IFN-/ (Herrmann et al., 2007, 
Farrell et al., 1979). The ISG15 protein is composed of two ubiquitin-like domains that can 
modify substrate proteins similarly to ubiquitin (Jeon et al., 2010). In addition, the C-
terminus of ISG15 contains the Gly-Gly motif which is required for ISG15 conjugation to 
target proteins. ISG15ylation requires the aid of an E1 activating protein, an E2 conjugating 
protein, and an E3 ligase protein. First, the ISG15-specific E1 activating protein, Ube1L, uses 
ATP to adenylate the Gly-Gly motif of ISG15. Ube1L then forms a thioester bond between its 
catalytic cysteine residue and the C-terminal Gly residue of ISG15. With the help of the E2 
conjugating protein, UbcH8, and a substrate-specific E3 ligase, ISG15 forms a covalent bond 
with the  -NH2 of a substrate lysine residue (reviewed in (Kerscher et al., 2006)). 
Importantly, ISG15 is conjugated to both viral and host proteins, and can have an antiviral 
effect by altering the activity of substrate proteins required for viral propagation (Harty et 
al., 2009, Shi et al., 2010). 
ISG15ylation has been implicated in restriction of HIV-1 replication  at the budding stage of 
the HIV-1 lifecycle (Okumura et al., 2006, Pincetic et al., 2010). The HIV-1 Gag protein 
contains a late-budding or L domain that has a PTAP motif, and can interact with 
endosomal sorting complex required for transport (ESCRT)-I. Specifically, tumour 
susceptibility gene 101 (TSG101), a component of ESCRT-I, interacts with the PTAP motif on 
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the HIV-1 Gag protein, and subsequently recruits ESCRT-II and ESCRT-III (VerPlank et al., 
2001). ESCRT-III promotes viral budding and the recruitment of vacuolar protein sorting 
(Vps4), an ATPase that releases ESCRT factors from the membrane (reviewed in (Usami et 
al., 2009)(Williams & Urbe, 2007)). Interestingly, ISG15 has been shown to interrupt the 
interaction between TSG101 and the HIV-1 Gag protein; however, neither TSG101 nor HIV-1 
Gag are directly modified with ISG15 (Okumura et al., 2006). ISG15 was also shown to 
interfere with the recruitment of Vps4 to the HIV-1 budding complex; however, the 
mechanism of this interruption has not yet been characterized. It is possible that charged 
multi-vesicular body protein CHMP-5, a component of ESCRT-III, prevents the recruitment 
of Vps4 as it was shown to be ISG15ylated (Pincetic et al., 2010). Further characterization of 
ISG15-mediated HIV-1 restriction is required to understand the antiviral effects of ISG15 on 
HIV-1 budding.  
7. Lifecycle target: HIV-1 release 
7.1 Tetherin 
7.1.1 Tetherin: History and structure 
For the past two decades, scientists have known that the HIV-1 Vpu protein is required for 
efficient release of virus particles (Gottlinger et al., 1993). HIV-1 particles lacking Vpu 
(HIV∆Vpu) cannot release properly from certain cells; however, until recently the cause of 
this phenotype was unknown (Varthakavi et al., 2003). Tetherin (also known as BST-2 and 
CD317) was first suggested to be an antiviral protein in 2006, when it was shown to target 
the K5 protein of Kaposi’s sarcoma-associated herpes virus (Bartee et al., 2006). A few years 
later, tetherin was identified as the causative agent of the HIVΔVpu phenotype when it was 
shown to inhibit the release of HIVΔVpu particles at the cell membrane of certain restrictive 
cells such as the HeLa cell line (Neil et al., 2008).  
Tetherin is an interferon-induced, transmembrane protein that contains a short cytoplasmic 
N-terminus, a transmembrane region, an ectodomain, and a C-terminal 
glycosylphosphatidylinositol (GPI) anchor (Kupzig et al., 2003). Both the transmembrane 
region and the ectodomain are made from a single alpha helix, and the ectodomain contains 
an additional coiled-coil region. Tetherin exists as a homodimer, which is formed by 
disulphide bridges between the coiled-coil ectodomain regions of two tetherin proteins. 
Importantly, tetherin dimerization has been shown to be crucial for HIV∆Vpu restriction 
(Andrew et al., 2009).  
7.1.2 Tetherin-mediated restriction of HIV-1 release 
Currently, the precise mechanism of tetherin-induced HIV∆Vpu restriction is uncertain. 
Among the proposed models, two aspects seem to be consistent: 1) tetherin proteins form 
homodimers via the coiled-coil regions in their ectodomains and 2) the N- and C-terminus 
of tetherin are incorporated into the cell and/or viral membrane (Perez-Caballero et al., 
2009). Tetherin homodimers localize to the cell membrane where they associate with HIV-1 
Gag oligomers on lipid rafts (where budding of the virus occurs) (Neil et al., 2008, Nguyen 
& Hildreth, 2000). Details of the tethering mechanism underlying restriction are poorly 
understood. One favourable hypothesis involves the C-terminal GPI being anchored to the 
cell membrane and the N-terminal transmembrane region being associated with the Gag 
oliogomers of the budding virus. As budding occurs, the cell membrane-bound C-terminus 
tethers the budding virus to the cell via the virion-bound N-terminus (Perez-Caballero et al., 
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2009). Conversely, the N-terminal transmembrane region of tetherin may anchor to the cell 
membrane whereas the GPI terminus may associate with the budding virus. Another 
plausible hypothesis is that one tetherin molecule binds to the cell membrane and another 
tetherin molecule binds to the budding virus. In this case, HIV-1 release would be inhibited 
by the interaction between coiled-coil regions in the tetherin dimer (Perez-Caballero et al., 
2009) (Figure 10).   
In spite of tetherin-induced restriction of HIVΔVpu virus, trapping virus at the membrane is 
not sufficient to prevent cell-to-cell transmission of HIV-1 (Casartelli et al., 2010, Kuhl et al., 
2010). This binding leads to efficient cell-to-cell transmission of the virus. Interestingly, 
tetherin has also been shown to prevent HIV-1 transmission through this route. Specifically, 
tetherin appears to link budding HIV-1 particles together in a chain-like fashion, tethering 
them to the cell membrane in viral aggregates (Hammonds et al., 2010). The formation of 
these aggregates prevents HIV-1 transmission through the virological synapse, possibly 
because the aggregates cannot fuse properly to the target cells (Casartelli et al., 2010). It is 
possible that tetherin is incorporated into the budding virions and that this causes abnormal 
virus fusion to the target cell; however, more studies are needed to confirm the presence of 
tetherin in HIV-1 particles and further define its role in HIV-1 restriction at the virological 
synapse. Taken as a whole, current research suggests that tetherin may have two roles in 
HIV-1 restriction: tethering virus particles to the cell membrane and preventing cell-to-cell 
transmission of HIV-1 to uninfected target cells.  
 
 
Fig. 10. Tetherin-induced inhibition of HIV-1 particle release. Each model centres on the 
dimerization of two tetherin molecules. In model 1, the N-terminal transmembrane regions 
of the tetherin dimer anchor to the cell surface and the C-terminal GPI domains associate 
with the budding virus. Model 2 is the opposite of model 1. In model 3, each tetherin 
molecule of the dimer associates with either only the budding virus or only the cell 
membrane, and HIV-1 restriction depends on the interaction between the coiled-coil regions.  
www.intechopen.com
  
HIV and AIDS – Updates on Biology, Immunology, Epidemiology and Treatment Strategies 
 
162 
7.1.3 Countermeasures to tetherin-mediated HIV-1 restriction 
The HIV-1 Vpu protein has been shown to degrade tetherin, thus abolishing its anti-HIV-1 
effects. Specifically, the transmembrane domain of Vpu can bind to tetherin, and this 
domain is necessary for Vpu localization to the cell membrane and subsequent association 
with tetherin (Kobayashi et al., 2011, Skasko et al., 2011, Vigan & Neil, 2010). Interestingly, 
mutating a single amino acid in the Vpu transmembrane domain (A18H) traps Vpu in the 
endoplasmic reticulum, where it is unable to translocate to the cell membrane or degrade 
tetherin (Skasko et al., 2011). Furthermore, it has recently been shown that four amino acids 
in the Vpu transmembrane domain (I34, L37, L41, and T45) are necessary for Vpu 
interaction with and antagonism of tetherin (Kobayashi et al., 2011). Mutational experiments 
with tetherin show that its transmembrane domain is also important for Vpu-tetherin 
interactions. Given this data, it is likely that Vpu and tetherin interact through their 
respective transmembrane domains and thus, that these domains are critical for Vpu-
mediated tetherin degradation.  
There are currently two major hypotheses for the mechanism of Vpu-mediated tetherin 
degradation. The first hypothesis involves tetherin degradation at a post-translational step, 
as there is no decrease in tetherin transcript levels in the presence of Vpu, but there is a 
decrease in protein expression (Douglas et al., 2009, Mangeat et al., 2009). It is possible that 
this degradation is mediated by Vpu binding to ǃ-transducin repeat-containing protein (ǃ-
TrCP), which is a substrate adaptor for a multi-subunit E3 ligase complex and is able to 
interact with Vpu through its C-terminus. The consequence of Vpu binding to the ǃ-TrCP-
E3 ligase complex is the ubiquitination of cell surface proteins, including tetherin, on lysine 
residues at positions 18 and/or 21 (Mangeat et al., 2009, Guatelli, 2009, Iwabu et al., 2009, 
Pardieu et al., 2010). Tetherin ubiquitination leads to its endocytosis from the cell membrane 
and degradation through either the proteasomal or lysosomal degradation pathways 
(Douglas et al., 2009, Mitchell et al., 2009, Van Damme et al., 2008).   
Tetherin degradation by Vpu and the ǃ-TrCP-E3 ligase complex however, is insufficient to 
explain one interesting finding: Vpu constructs that contain mutations in the motif that 
recognizes ǃ-TrCP can still partially, or in some cases totally, overcome tetherin-mediated 
HIV-1 restriction (Douglas et al., 2009, Mangeat et al., 2009, Mangeat et al., 2009, Mitchell et 
al., 2009, Miyagi et al., 2009). Thus, a second hypothesis has been proposed that involves 
tetherin degradation in late endosomal compartments. It has previously been shown that 
Vpu is distributed throughout the trans-golgi network, and that it can modulate tetherin cell 
surface expression by sequestering it intracellularly. Sequestration of tetherin prevents its 
anterograde trafficking to the cell membrane and subsequently delivers it to late endosomal 
compartments (Dube et al., 2010, Dube et al., 2010, Hauser et al., 2010). Of note, the specifics 
of this mechanism of Vpu-mediated degradation are still largely uncharacterized and 
further studies are needed to elucidate the details of this mechanism. However, taken 
together, current research suggests that there may be two mechanisms by which Vpu 
counteracts the antiviral activity of tetherin.   
8. Conclusion 
8.1 Pharmaceutical approach 
In the future, it is probable that new HIV-1 therapies will be developed based on the actions 
of cellular restriction factors. Currently, many studies are focused on defining the molecular 
mechanisms of these factors; however, it is still unclear how this information will be used to 
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create effective therapies. In the short-term, drug-based therapies are the most likely to be 
successful, and due to the constant development of HIV-1 resistance, new drugs are always 
needed. To date, there are 32 antiretroviral drugs approved by the FDA, and none of these 
drugs target the same steps in the HIV-1 lifecycle as cellular restriction factors. This makes 
restriction factors excellent candidates for drug design, specifically proteins such as TRIM22 
or ISG15, which do not appear to be directly targeted by any HIV-1 proteins. With the 
development of any new HIV-1 drug, resistance is always a concern; however, identifying 
new stages of the HIV-1 lifecycle to antagonize may reduce viral replication enough to 
prevent escape mutants.  
Alternatively, drugs targeting cellular restriction factor antagonists could be developed. For 
example, the HIV-1 Vif protein antagonizes APOBEC3 by marking it for proteasomal 
degradation (Yu et al., 2003). Inhibiting the interaction between APOBEC3 and Vif may 
prevent this degradation, and many studies have focused on identifying important 
interacting regions on both proteins (Chen et al., 2009, Huthoff & Malim, 2007, Yamashita et 
al., 2008). Unfortunately, many of the interacting regions on Vif differ depending on the 
specific APOBEC3 protein it is interacting with, and it is likely that three-dimensional 
structures of APOBEC3 proteins bound to Vif will be needed to effectively target this 
interaction (Russell et al., 2009, Tian et al., 2006). Despite these challenges, one small 
molecule antagonist of Vif was recently identified (RN-18) and shown to decrease levels of 
Vif protein in vitro (Nathans et al., 2008). It will be interesting to follow-up this research in 
vivo, and learn whether RN-18 has an effect on HIV-1 replication in infected individuals. 
Finally, another option to shield APOBEC3 from Vif involves designing a molecule that 
binds to APOBEC3 and prevents this interaction; however, this molecule would also have to 
preserve APOBEC3’s antiviral function (Albin & Harris, 2010).  
The HIV-1 Tat protein is another attractive drug target, since it is essential for HIV-1 
replication and antagonizes two HIV-1 restriction factors (PKR and OAS1). For unknown 
reasons, Tat hasn’t received much attention as a potential drug target, possibly because its 
actions are hard to re-create in vitro. However, inhibition of Tat potently inhibits HIV-1 
replication, and further research in this area is certainly warranted. Drugs that target the 
HIV-1 Vpu protein could also be considered; however, because Vpu is not critical for HIV-1 
replication in vivo it may not be an ideal candidate (Friborg et al., 1995, Terwilliger et al., 
1989). Conversely, drugs that mimic the effects of tetherin, but are resistant to Vpu, may 
successfully reduce HIV-1 replication. In fact, an artificial Vpu-resistant tetherin protein was 
recently engineered; however, it has not yet been tested in clinical trials (Perez-Caballero et 
al., 2009). Inhibiting the action of host proteins that assist HIV-1 replication is another 
possibility. For example, cyclophilin A (CypA) is required for HIV-1 replication, and 
without Cyp A HIV-1 virions are not infectious (Sokolskaja & Luban, 2006, Thali et al., 
1994). Small molecule inhibitors targeting Cyp A may block HIV-1 replication at the 
uncoating stage, and targeting a host protein avoids the problem of viral resistance. 
However, HIV-1 propagation in the absence of Cyp A may allow HIV-1 variants to evolve 
that no longer require Cyp A for replication.  
8.2 Gene therapy approach 
An alternative approach to HIV-1 therapy involves using cellular restriction factors in 
conjunction with gene therapy. In this approach, DNA encoding one or more cellular 
restriction factors is inserted into target cells to interfere with HIV-1 infection or replication. 
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One advantage of this approach is that cellular restriction factors are naturally expressed in 
human cells, and as such may be less toxic or immunogenic in vivo (Barr, 2010). Since there 
are no known viral countermeasures to TRIM22, Rhesus TRIM5ǂ or ISG15, these proteins 
are currently the best candidates for gene therapy. Another possibility involves using 
molecular engineering to create modified restriction factors that are resistant to viral 
antagonists, making them more suitable candidates for gene therapy. For example, a human 
protein modeled after the TRIM5ǂ-CypA fusion protein in Owl monkeys was recently 
engineered, and shown to block HIV-1 replication in primary CD4+ T-cells and macrophages 
(Neagu et al., 2009). In addition, mice engrafted with inhibitor-expressing CD4+ T-cells had 
decreased viremia and increased levels of CD4+ T-cells. It is possible that this human 
TRIM5ǂ-CypA protein could be used for gene therapy, and it is likely that it will be tested 
clinically in the near future.  
Since many cellular restriction factors are IFN-inducible, they are not constitutively 
expressed in cells. As such, it is desirable to employ a gene therapy approach that mimics 
this pattern of expression. One interesting strategy involves creating a construct that 
contains restriction factor genes under the control of the HIV-1 LTR promoter. In this 
strategy, target cells are preloaded with the construct, and when HIV-1 infects these cells, 
Tat expression activates transcription of the LTR-fused restriction factor genes. Restriction 
factor expression reduces HIV-1 replication in infected cells, limiting further propagation of 
the virus. Notably, this approach has been successfully tested in vitro using the restriction 
factors PKR, OAS1 and ISG15; however, more experiments are needed to validate this 
strategy in vivo, and to test various construct delivery methods (Muto et al., 1999, Schroder 
et al., 1990a, Su et al., 1995). Gene therapy continues to be a promising approach for the 
treatment of HIV/AIDS; however, several problems need to be addressed before this 
technology can be fully realized. Some of these issues include, but are not limited to, 
increasing the stability of DNA and longevity of target cells, avoiding adverse immune 
responses, and targeting specific cells or tissues.  
8.3 Additional approaches 
8.3.1 Nanotechnology 
Nanotechnology is revolutionizing many areas of medicine, particularly in the realm of 
drug delivery. With nanotechnology, it is now possible to target drugs to specific cells or 
tissues, a method that could be used to direct antiretroviral drugs to CD4+ T-cells and 
macrophages (Farokhzad, 2008, Farokhzad & Langer, 2009). In addition, targeted antiviral 
delivery to the brain or other organs could ensure that drugs reach latent HIV-1 reservoirs 
(Vyas et al., 2006, Vyas et al., 2006, Amiji et al., 2006). The development of controlled-release 
delivery systems could also allow antiretroviral drugs to be released over longer times, and 
enhance their half-lives. For example, a new anti-HIV-1 drug called Rilpivirine was recently 
administered to dogs and mice in nanosuspensions (Baert et al., 2009). This resulted in the 
sustained release of the drug over 3 months in dogs and 3 weeks in mice, compared to a 
half-life of 38 hours for free drug. Importantly, this type of drug delivery system could have 
major implications in reducing antiretroviral toxicity and improving drug adherence. Thus, 
nanotechnology should be considered in the development of new antiretroviral drugs, 
including drugs that mimic the effects of cellular restriction factors.  
In addition to improving antiretroviral therapies, there are ongoing efforts to apply 
nanotechnology to gene therapy. Early attempts in gene therapy for HIV/AIDS have used 
viral vectors as gene delivery systems, with some encouraging results (Li et al., 2005, Morris 
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& Rossi, 2006, Morris & Rossi, 2006, Lee et al., 2005, Lee et al., 2005). However, the use of 
viral vectors for gene delivery poses several potential problems such as toxicity, 
immunogenicity, and insertion mutagenesis. As such, the use of non-viral vectors for gene 
delivery must be further explored, and nanotechnology is one promising option (Lundin et 
al., 2009, Mintzer & Simanek, 2009). One example is the use of RNA interference (RNAi) for 
HIV/AIDS therapies. RNAi may have therapeutic potential in the treatment of HIV/AIDS; 
however, delivery of siRNA to specific cells continues to be a problem (Haasnoot et al., 2007, 
Haasnoot et al., 2007, Whitehead et al., 2009, Whitehead et al., 2009, Berkhout & ter Brake, 
2009). Nanosuspensions of siRNA are currently being tested in humans for cancer 
treatment, and have recently entered Phase I clinical trials (Davis, 2009). If this technique is 
successful, it could be applied to cellular restriction factor-based HIV/AIDS gene therapy. 
For example, nanosuspensions of siRNA could be targeted to HIV-1-infected cells to 
knockdown the viral mRNA of restriction factor antagonists, such as Vif, Tat and Vpu. This 
would increase the antiviral activity of restriction factors, specifically reducing HIV-1 
replication in infected cells. Alternatively, DNA from one or more cellular restriction factors 
could be delivered to HIV-1 infected cells using nanotechnology platforms. This may 
provide a safe and effective way to deliver cellular restriction factor genes to HIV-1 infected 
cells.  
8.3.2 Zinc finger nucleases 
Zinc finger nucleases (ZFN) have recently emerged as an important technology for gene 
modification, and there are several potential applications for ZFNs in HIV/AIDS therapy. 
ZFNs function by inducing a double-stranded break in a specific DNA sequence and 
generate the desired gene modification during DNA repair (Urnov et al., 2010). One of the 
main advantages of ZFNs is that the changes they make are both permanent and heritable, 
eliminating the need for persistent therapeutic intervention. For HIV-1, most ZFN research 
has focused on the manipulation of the human CCR5 gene, which encodes one of HIV-1’s 
co-receptors and is required for viral entry into the host cell. Deletion of a 32-bp region from 
this gene (CCR5Δ32) results in a non-functional receptor, and people with this mutation are 
resistant to HIV-1 infection (Huang et al., 1996). Thus far, ZFN researchers have succeeded 
in deleting the 32-bp region from the human CCR5 gene, both in primary CD4+ T-cells and 
hematopoietic stem cells (Bobis-Wozowicz et al., 2011, Lei et al., 2011, Perez et al., 2008). 
Furthermore, there are two Phase I clinical trials in progress testing the efficacy of ex vivo 
expansion and infusion of these modified cells in HIV-1 infected individuals (Urnov et al., 
2010).  
In addition to gene deletion, ZFNs have also been used successfully for gene correction 
(allele editing) and gene addition (Urnov et al., 2005, Urnov et al., 2005, Moehle et al., 2007). 
Both gene correction and addition may be useful for cellular restriction factor-based HIV-1 
therapies; however, to date this has never been experimentally tested. For example, the 
addition of one or more cellular restriction factor genes to HIV-1 target cells may produce a 
‘super-restrictive’ phenotype, whereby cells with multiple genes express higher levels of 
restriction factor proteins, thus increasing their capacity to fight HIV-1 infection. Several 
HIV-1 restriction factors have been shown to be more effective restrictors when expressed at 
higher levels. For example, higher expression of TRIM22 was recently shown to be 
correlated with lower levels of viremia and higher CD4+ T-cell counts in HIV-1-infected 
individuals (Singh et al., 2011). Another possibility involves adding cellular restriction factor 
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genes to hematopoietic stem cells, allowing the generation of ‘super-restrictive’ cells in all 
blood lineages (including macrophages and dendritic cells, which are often the first cells to 
encounter HIV-1 in vivo). However, many more studies need to be performed, particularly 
to identify any deleterious effects caused by amplified expression of cellular restriction 
factors.  
8.3.3 Next-generation sequencing 
Next-generation sequencing is another new and exciting technology that has potential 
applications in HIV/AIDS therapy. With this calibre of sequencing, it is now possible to 
read hundreds of DNA samples simultaneously, an approach that has helped researchers 
identify polymorphisms in different human genes. It is well known that people differ 
significantly in their susceptibility to HIV-1 infection and disease progression to AIDS, and 
polymorphisms in cellular restriction factors may contribute to these differences (Ball et al., 
2007, Beyrer et al., 1999, Cao et al., 1995). For example, there is research suggesting that 
various polymorphisms in the TRIM5ǂ and APOBEC3 genes contribute to HIV-1 disease 
progression; however, due to confounding reports further research is needed in this area 
(van Manen et al., 2008, van Manen et al., 2008, An et al., 2009, Goldschmidt et al., 2006, 
Harari et al., 2009, Valcke et al., 2006). In addition, polymorphisms in other cellular 
restriction factors may influence the clinical course of HIV-1 infection, but many of these 
factors have never been tested. In the future, it may be possible to generate an individual’s 
cellular restriction factor polymorphism “blueprint”(Barr, 2010). This blueprint could help 
predict a person’s susceptibility to HIV-1 infection and progression to AIDS, and may 
potentially lead to a more personalized HIV-1 treatment regime. Alternatively, with the 
advent of ZFN technology it may also be possible to “edit” multiple restriction factor genes 
(change disadvantageous polymorphisms to advantageous polymorphisms) to create an 
optimal cellular restriction factor blueprint in vivo, and better equip individuals to fight 
HIV-1 infection.  
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